Anticoagulation/Thromboembolism
RSSArticles
-
Bioabsorbable Coronary Scaffolds: Promise and Peril
Clinical outcomes from percutaneous coronary intervention (PCI) have steadily improved over time, with transitions from balloon angioplasty to bare-metal stenting, and more recently from first-generation drug-eluting stents (DES) to second- and third-generation designs. -
Is Left Atrial Appendage Occlusion with the Watchman Device a Reasonable Alternative to Anticoagulation with Warfarin?
The goal of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy (PREVAIL) trial was to assess the safety and efficacy of left atrial appendage (LAA) occlusion for stroke prevention in patients with atrial fibrillation (AF) compared with long-term warfarin therapy -
Is Less More? Transfemoral TAVR: The Minimalist Approach
Since its initial FDA approval in November 2011, transcatheter aortic valve replacement (TAVR) has rapidly gained acceptance as a standard therapy in the United States. -
Predicting Sudden Death Risk in Hypertrophic Cardiomyopathy
-
Renin-angiotensin System Antagonists in Stable CAD
-
Prehospital Ticagrelor Administration in STEMI Patients Falls Short
-
Is There a Role for Routine Procainamide Infusion in the Evaluation of Patients with Cardiac Arrest?
-
Peri-procedural Management of New Oral Anticoagulants
-
FFR in Stable Coronary Artery Disease: A Second Chance at FAME?
-
PCI vs. CABG in High-Risk Patients